We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Solventum (SOLV - Free Report) is expected to reveal quarterly earnings of $1.35 per share, indicating a decline of 10% compared to the year-ago period. Analysts forecast revenues of $1.97 billion, representing a decline of 6% year over year.
Over the last 30 days, there has been a downward revision of 3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Solventum metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales- MedSurg' reaching $1.19 billion. The estimate indicates a change of -1.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Health Information Systems' will reach $357.95 million. The estimate points to a change of +3.8% from the year-ago quarter.
Analysts expect 'Net Sales- Dental Solutions' to come in at $315.90 million. The estimate indicates a year-over-year change of -7.1%.
Shares of Solventum have demonstrated returns of -2.6% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #3 (Hold), SOLV is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Solventum (SOLV - Free Report) is expected to reveal quarterly earnings of $1.35 per share, indicating a decline of 10% compared to the year-ago period. Analysts forecast revenues of $1.97 billion, representing a decline of 6% year over year.
Over the last 30 days, there has been a downward revision of 3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Solventum metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales- MedSurg' reaching $1.19 billion. The estimate indicates a change of -1.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Health Information Systems' will reach $357.95 million. The estimate points to a change of +3.8% from the year-ago quarter.
Analysts expect 'Net Sales- Dental Solutions' to come in at $315.90 million. The estimate indicates a year-over-year change of -7.1%.
View all Key Company Metrics for Solventum here>>>Shares of Solventum have demonstrated returns of -2.6% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #3 (Hold), SOLV is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .